Rationale association sulfonylurea insulin patients non-insulin-dependent diabetes NIDDM sulfonylureas treatment primary failure patients secondary failure therapy rate year hand insulin-treated NIDDM patients progressive increase insulin requirement significant improvement glucose control patients combination oral agents insulin therapy useful rationale therapeutic approach resides synergistic action agents specific mechanisms responsible glucose intolerance hyperglycemia Long-acting insulin single dose supper bedtime excessive overnight hepatic glucose production significant reduction glucose concentrations ambient glucose level stimulatory effect sulfonylureas insulin secretion Sulfonylurea treatment portal inflow secreted insulin resultant increase insulin levels liver postprandial hepatic glucose output sulfonylureas insulin action target tissue muscle overall insulin-mediated glucose metabolism reduction plasma glucose levels toxic effect hyperglycemia beta-cell insulin-sensitive tissues basis NIDDM patients secondary failure monotherapy combined therapy Nevertheless effects combined therapy intensive insulin therapy poor control 